Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-02
2007-10-02
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
11156082
ABSTRACT:
The present invention relates to the use of known 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position and cGMP PDE-inhibitory properties for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
REFERENCES:
patent: 6362178 (2002-03-01), Niewohner et al.
patent: 6890922 (2005-05-01), Niewohner et al.
patent: 6930108 (2005-08-01), Niewohner et al.
patent: 594671 (1978-01-01), None
patent: 2255172 (1973-05-01), None
patent: 2364076 (1974-07-01), None
patent: 2811780 (1978-09-01), None
patent: 198 12 462 (1999-09-01), None
patent: 0009384 (1980-04-01), None
patent: 1 020 190 (2000-07-01), None
patent: 1097711 (2001-05-01), None
patent: 1092719 (2003-05-01), None
patent: 1 317 924 (2003-06-01), None
patent: 2213058 (1974-08-01), None
patent: 9428902 (1994-12-01), None
patent: 9924433 (1999-05-01), None
patent: 9967244 (1999-12-01), None
patent: 02064593 (2002-08-01), None
Miyara, M., et al., “Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021”, Eur. J. Pharm., 284: 25-33 (1995).
Beavo, J. A., et al., “Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors”, TIPS, 11: 150-155 (Apr. 1990).
Fawcett, L., et al., “Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A”, PNAS, 97(7): 3702-3707 (Mar. 2000).
Stoclet, J.-C., et al., “Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases”, Exp. Opin. Invest. Drugs. 4(11): 1081-1100 (1995).
Cecil Textbook of Medicine, 21stEd. vol. 1, Goldman et al. (eds.), published 2000 by W. B. Saunders Co., pp. 1060-1074.
International Search Report dated Nov. 22, 2006 in EP 06017257.4-1216.
Uckert St et al: “Functional in vitro effects of cAMP/cGMP modulating drugs on human detrusor smooth muscle” Journal fur Urologie Und Urogynakologie 2002, Austria.
Bandel Tiemo-Joerg
Barth Wolfgang
Bischoff Erwin
Haning Helmut
Niewohner, legal representative Maria Theresia
Bayer HealthCare AG
Henley III Raymond J.
LandOfFree
Use of 2-alkoxyphenyl-substituted imidazotriazinones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 2-alkoxyphenyl-substituted imidazotriazinones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 2-alkoxyphenyl-substituted imidazotriazinones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876123